Sellas Life Sciences Announces Entry into Cooperative Research and Development Agreement with National Heart, Lung and Blood Institute, National Institutes of Health

News Goal of the collaborative effort is to develop an effective testing method to monitor minimal residual disease (MRD) and to develop diagnostic testing for acute myeloid leukemia. Contributed Author:  Sellas Life Sciences Group Topics:  Medical Diagnostics